Hims & Hers Health, Inc. HIMS
We take great care to ensure that the data presented and summarized in this overview for Hims & Hers Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HIMS
View all-
Vanguard Group Inc Valley Forge, PA20.3MShares$647 Million0.01% of portfolio
-
Black Rock Inc. New York, NY14.6MShares$465 Million0.01% of portfolio
-
New View Hms Spv Partners, LLC Burlingame, CA9.66MShares$308 Million100.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA8.38MShares$267 Million1.08% of portfolio
-
State Street Corp Boston, MA7.77MShares$248 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.95MShares$222 Million0.27% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA6.3MShares$201 Million0.13% of portfolio
-
Goldman Sachs Group Inc New York, NY5.54MShares$177 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA4.33MShares$138 Million0.01% of portfolio
-
Morgan Stanley New York, NY4.03MShares$129 Million0.01% of portfolio
Latest Institutional Activity in HIMS
Top Purchases
Top Sells
About HIMS
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Insider Transactions at HIMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2025
|
Melissa Baird Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
67,687
-1.71%
|
$2,369,045
$35.48 P/Share
|
|
Mar 26
2025
|
Melissa Baird Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
67,687
+7.63%
|
$0
$0.4 P/Share
|
|
Mar 21
2025
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,118
-15.17%
|
$739,776
$32.41 P/Share
|
|
Mar 18
2025
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
8,277
-44.77%
|
$281,418
$34.31 P/Share
|
|
Mar 18
2025
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,236
-1.83%
|
$110,024
$34.31 P/Share
|
|
Mar 18
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
78,760
-25.69%
|
$2,599,080
$33.94 P/Share
|
|
Mar 18
2025
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
23,287
-10.0%
|
$791,758
$34.31 P/Share
|
|
Mar 17
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
47,534
-5.64%
|
$1,568,622
$33.85 P/Share
|
|
Mar 17
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
128,127
-10.19%
|
$4,228,191
$33.44 P/Share
|
|
Mar 17
2025
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
125,335
+12.54%
|
$250,670
$2.43 P/Share
|
|
Mar 14
2025
|
Irene Becklund PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,813
-29.71%
|
$257,829
$33.14 P/Share
|
|
Mar 14
2025
|
Irene Becklund PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,097
+47.81%
|
-
|
|
Mar 14
2025
|
Christiane Pendarvis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,211
+36.36%
|
-
|
|
Mar 14
2025
|
Soleil Boughton Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,798
-11.87%
|
$785,334
$33.14 P/Share
|
|
Mar 14
2025
|
Soleil Boughton Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,210
+17.73%
|
-
|
|
Mar 14
2025
|
Oluyemi Okupe Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
51,671
-25.32%
|
$1,705,143
$33.14 P/Share
|
|
Mar 14
2025
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
93,718
+31.47%
|
-
|
|
Mar 14
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
97,551
-35.6%
|
$3,219,183
$33.14 P/Share
|
|
Mar 14
2025
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
176,311
+39.15%
|
-
|
|
Mar 14
2025
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,162
-1.34%
|
$104,346
$33.14 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 115K shares |
|---|---|
| Exercise of conversion of derivative security | 7.4M shares |
| Payment of exercise price or tax liability | 1.12M shares |
|---|---|
| Open market or private sale | 7.14M shares |
| Bona fide gift | 10K shares |